Currently, there are no approved topicals for the treatment of prurigo nodularis. According to the presenter, ruxolitinib cream 1.5% could become the first. ORLANDO — Ruxolitinib cream 1.5% ...

Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a phase 3 trial shows.

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN ... After 12 weeks of treatment, 44.6% of ...

In prurigo nodularis, ruxolitinib cream significantly improves itch and treatment success, indicating its potential as a novel therapy. Two posters presented at the 2025 American Academy of ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from povorcitinib treatment, Incyte announced in a press release.

The first one being that it was able to report positive data from one of its two phase 3 studies using OPZELURA [Ruxolitinib Cream 1.5%] for the treatment of patients with Prurigo Nodularis [PN].

The authorisation in prurigo nodularis was supported by data from the phase 3 OLYMPIA 1 and 2 trials, which met both primary and key secondary endpoints, demonstrating that treatment with Nemluvio ...

“We’re bringing impactful new science to this year’s AAD meeting, with new data on Nemluvio – our treatment for prurigo nodularis and atopic dermatitis – and the latest from our ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Treatment-emergent adverse events (TEAEs ... et al "Efficacy and safety of ruxolitinib cream in patients with prurigo nodularis: Results from a phase III, randomized, vehicle-controlled study ...